Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Chandrima Sanyal

Novo Nordisk's Stock Slump Shows The GLP‑1 Trade's Side Effect: ETF Concentration Risk

Novo Nordisk

Novo Nordisk’s (NYSE:NVO) nearly 11% pre-market drop on Monday and subsequent 9% dip at market open, in the aftermath of disappointing topline results from its evoke/evoke+ Alzheimer’s trials, is more than a pipeline setback.  It’s a stress test for healthcare ETFs that have quietly become GLP-1 momentum vehicles. With two years of outperformance powered by Novo’s Ozempic and Wegovy, and Eli Lilly‘s (NYSE:LLY) Mounjaro and Zepbound, many ETFs now live and die by the swings of just two companies: Novo and Eli Lilly.

Where ETF Exposure Is Heaviest

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.